



assessments during the selection process. The availability of purified, full-length human IgGs allows for rapid determination of biologic function and potential therapeutic efficacy. Adimab offers fundamental advantages by delivering and optimizing diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and developability.

With more than 30 antibody discovery projects in the last three years, Adimab has become the industry's most sought after partner for the development of therapeutic human antibodies. Adimab has enabled its partners, including Biogen Idec, Eli Lilly, Genentech, Gilead, Human Genome Sciences, Merck, Novartis, Novo Nordisk, Pfizer, and Roche to expand their biologics pipelines through a range of technology access arrangements. Less than three years after Adimab launched its platform several antibodies discovered by Adimab have entered human clinical trials providing further evidence for the quality and speed of the platform. For more information, visit [www.adimab.com](http://www.adimab.com).

### **About Mersana**

[Mersana](http://www.mersana.com) engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. Utilizing its proprietary [conjugation technology](#), which is comprised of the Fleximer® polymer and a broad array of customizable linker chemistries, Mersana is developing a portfolio of next-generation antibody-drug conjugates (ADCs) with superior properties not found with other ADC technologies. Mersana is currently working with a number of top Pharma companies to develop next generation Fleximer-ADCs and most recently announced a \$270 million collaboration with Endo Pharmaceuticals in March, 2012. The company is also advancing its own [pipeline](#) of next-generation drugs with best-in-class potential to address unmet needs and improve patient outcomes in multiple oncology indications. Mersana was founded by PureTech Ventures, LLC and a group of leading academics and clinicians.

For more information, visit [www.mersana.com](http://www.mersana.com).

Fleximer® is a trademark of Mersana Therapeutics, Inc.

#### Business Contacts:

Guy Van Meter  
VP of Business Development  
Adimab, LLC.  
(603) 643-7110 x175

Michael Metzger  
EVP & Chief Operating Officer  
Mersana Therapeutics, Inc.  
(617) 715-8236

Media Contacts:

MacDougall Biomedical Communications

(781) 235-3060

For Adimab: Chris Erdman

For Mersana: Jennifer Conrad